Literature DB >> 11181360

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

J Li1, J Turnidge, R Milne, R L Nation, K Coulthard.   

Abstract

The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were >128 mg/liter. For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter. The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h. Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs. Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of P. aeruginosa infections in cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181360      PMCID: PMC90373          DOI: 10.1128/AAC.45.3.781-785.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics.

Authors:  Caroline Rynn; Mandy Wootton; Karen E. Bowker; H. Alan Holt; David S. Reeves
Journal:  Clin Microbiol Infect       Date:  1999-01       Impact factor: 8.067

Review 2.  Peptide antibiotics.

Authors:  R E Hancock; D S Chapple
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  INTRAVENOUS ADMINISTRATION OF SODIUM COLISTIMETHATE.

Authors:  R D BAINES; D RIFKIND
Journal:  JAMA       Date:  1964-10-26       Impact factor: 56.272

4.  POLYMYXIN B AND COLISTIN: IN VITRO ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA.

Authors:  T C EICKHOFF; M FINLAND
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

5.  The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MIC.

Authors:  W J Munckhof; D Olden; J D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

6.  Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.

Authors:  S P Conway; M N Pond; A Watson; C Etherington; H L Robey; M H Goldman
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

7.  Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis.

Authors:  J R Curitis; J B Eastwood
Journal:  Br Med J       Date:  1968-02-24

8.  A reassessment of the in-vitro activity of colistin sulphomethate sodium.

Authors:  C R Catchpole; J M Andrews; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1997-02       Impact factor: 5.790

9.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

10.  4-h Identification of Pseudomonas aeruginosa with 9-chloro-9-(4-diethylaminophenyl)-10-phenylacridan.

Authors:  J R Davis; C E Stager; G F Araj
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

View more
  73 in total

1.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard; Jason Valentine
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Authors:  Roberto Imberti; Maria Cusato; Giovanni Accetta; Valeria Marinò; Francesco Procaccio; Alfredo Del Gaudio; Giorgio A Iotti; Mario Regazzi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 4.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

5.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

7.  Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 8.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 10.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.